Concepedia

Author

Graham Cohen

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Atreya, Baddeley, C Anderson, G Cohen, G. Cohen, G. L. Cohen, G.L. Cohen, Graham Cohen, Graham L. Cohen, Graham Lawrence Cohen

31

Publications

8.8K

Citations

12

H-Index

25

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)The Maria Sklodowska-Curie National Research Institute of OncologyIstanbul University-CerrahpaşaNational Cancer Center Hospital EastThe Medical Oncology Centre of Rosebank
GC

About

Graham Cohen is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

5.2K

2

Health Sciences

3

3

234

3

Diagnostic Sciences

1

1

12

4

Gastroenterology

1

1

1.3K

5

Immunology

1

1

210

Graham Cohen

×

11

Publications

8.7K

Citations

11

H-Index

YearCitations

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba,

The Lancet

2019

3.2K

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil,

The Lancet

2019

3K

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu,

The Lancet Oncology

2021

627

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

John V. Heymach, Luis Paz‐Ares, Filippo de Braud,

Journal of Clinical Oncology

2008

219

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov,

The Lancet Oncology

2018

210

Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin

Carla I. Falkson, Graham Cohen

Oncology

1998

45

Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial

Thomas Powles, Yen‐Hwa Chang, Yoshiaki Yamamoto,

Nature Medicine

2024

27

Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy

Daniel Vorobiof, Bernardo L. Rapoport, Martin Chasen,

International Journal of Gynecological Cancer

2003

12

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.

Conrad Jacobs, Bernardo L. Rapoport, Sze Wai Chan,

Journal of Clinical Oncology

2021

12

Page 1